MedTrace Logo

Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

NCT04504331 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2026-02-12

Study results available
· View outcomes & findings →

Summary

The purpose of the study is identify the dose(s) of infigratinib to use in combination with tamoxifen to treat patients with a particular type of advanced breast cancer (hormone receptor-positive, HER2-negative, FGFR-altered breast cancer)

Conditions

Interventions

DRUG

Infigratinib

Oral dose

DRUG

Tamoxifen

Oral Dose

DRUG

Omnipaque 350

IV contrast agent

DRUG

Iopamidol

IV contrast agent

DIAGNOSTIC_TEST

Computed tomography (CT)

Computed tomography (CT) to assess disease state using Iopamidol and/or Omnipaque 350.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • QED Therapeutics, a BridgeBio company

    collaborator INDUSTRY

  • Jennifer Lee Caswell-Jin

    lead OTHER

Principal Investigators

  • Jennifer Lee Caswell-Jin · Stanford Universiy

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-13
Primary Completion
2021-10-22
Completion
2021-10-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04504331 on ClinicalTrials.gov